ArticleBiomedical engineering letters2025
Nanoengineered cytotoxic T cells for photoacoustic image-guided combinatorial cancer therapy.
Article in Biomedical engineering letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach.Progress in biomedical engineering (Bristol, England) · 2026Review
- Phase-change perfluorocarbon nanodroplets enable spatiotemporal control of ultrasound and photoacoustic imaging and therapy.Biomedical engineering letters · 2026Review
- Smart Cells Against Cancer: Advances in Cell-Based Drug Delivery and Diagnostics.Pharmaceutics · 2025Review
- Editorial: Monitoring the immune/tumor microenvironment to improve cancer immunotherapy.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
This study aims to demonstrate that surface engineering of cytotoxic T cells with drug-loaded nanoparticles enhances nanoparticle delivery to induce a more potent combinatorial chemotherapeutic and immunotherapeutic effect, as well as enabling spatial tracking through the use of non-invasive, real-time ultrasound-guided photoacoustic imaging. Ovalbumin (OVA)-targeting OT-1 T cells were functionalized with doxorubicin-loaded, mesoporous silica-coated gold nanorods. In vitro toxicity and synergistic effects were assessed using antigen-matched OVA-expressing melanoma cells, while in vivo studies evaluated therapeutic efficacy. Ultrasound-guided photoacoustic imaging was employed to confirm the targeted delivery of the nanoengineered cells. The integration of optically active, drug-loaded nanoparticles with T cells facilitates precise image-guided delivery and enhances nanoparticle accumulation within the tumor environment, thereby maximizing the combinatorial chemo-immunotherapeutic effect. The integration of optically active, drug-loaded nanoparticles with T cells facilitates precise image-guided delivery and enhances nanoparticle accumulation within the tumor environment, thereby maximizing the combinatorial chemo-immunotherapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.